Last reviewed · How we verify
NCT04757883: COVATRHUS
Immunological Follow-up After SARS CoV2 Vaccination in Kidney Transplant Recipients
trial testing Study of the synthesis of antibodies directed against SARS in Kidney Transplant Recipients in 37 participants. Terminated before completion.
1 November 2024
Quick facts
| Lead sponsor | University Hospital, Strasbourg, France |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 37 |
| Start date | 2 February 2021 |
| Primary completion | 1 November 2024 |
| Estimated completion | 1 November 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- Study of the synthesis of antibodies directed against SARS
Conditions studied
- Kidney Transplant Recipients — all drugs for Kidney Transplant Recipients →
Sponsor
University Hospital, Strasbourg, France
Who can join
18 and older, any sex, with Kidney Transplant Recipients. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators goal is to assess the vaccine response of kidney transplant patients following vaccination against SARS-CoV-2. The study population will be derived from cohorts of kidney transplant patients who have been transplanted for more than 3 months and have no contraindications to vaccination. These patients will be vaccinated as part of routine care with a CoV-2 SARS vaccine licensed in France. In this cohort, the investigators wish to study the post-vaccination humoral response by assaying neutralizing antibodies against SARS CoV-2 and the specific cellular response of SARS Cov-2 by quantiferon and in vitro lymphocyte stimulation assays.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients.
Charmetant X, Espi M, Benotmane I, Barateau V, et al · · 2022 · cited 61× · PMID 35103481 · DOI 10.1126/scitranslmed.abl6141 -
SARS-CoV-2 vaccination in patients receiving kidney replacement therapies: where are we now with the protective immune response?
Toapanta N, Bestard O, Soler MJ. · · 2021 · cited 5× · PMID 34289072 · DOI 10.1093/ndt/gfab227 -
Comparison of infected and vaccinated transplant recipients highlights the role of Tfh and neutralizing IgG in COVID-19 protection
Charmetant X, Espi M, Benotmane I, Heibel F, et al · · 2021 · cited 1× · DOI 10.1101/2021.07.22.21260852
Verify or expand the search:
- PubMed search for NCT04757883
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Transplant Recipients
Currently open trials in the same condition.
- NCT06751992 — Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients · Phase 4 · recruiting
- NCT07532694 — Diode Laser-Assisted Periodontal Therapy in Kidney Transplant Recipients · NA · recruiting
- NCT07370727 — Velocity-Based Resistance Training in Kidney Transplant Recipients · NA · recruiting
- NCT05938712 — The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist · Phase 2 · recruiting
- NCT05702398 — Pilot Trial of Supplemental Vitamin A and Nicotinamide · EARLY_PHASE1 · recruiting
Other University Hospital, Strasbourg, France trials
Trials by the same sponsor.
- NCT07418554 — Sleep Disturbances in Children and Adolescents With Post-traumatic Stress Disorder (PTSD): a Randomized Double-blind Pla · Phase 3 · not yet recruiting
- NCT07108582 — Reducing Chronic Pain After Lung Surgery: A Trial of Limiting NSAIDs During Recovery · Phase 3 · not yet recruiting
- NCT07302646 — Optimizing Reduced-Flow, Low-Volume Contrast Protocols for Cerebral Angiography in Unruptured Aneurysms · NA · not yet recruiting
- NCT07273968 — Clinical Study Evaluating the Effect of Virtual Reality on Reducing Patients' Anxiety During Wisdom Teeth Extraction · NA · not yet recruiting
- NCT07214103 — Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulop · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04757883 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Strasbourg, France
- Last refreshed: 19 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04757883.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing